The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus.

The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus.

Item
http://www.wikidata.org/entity/Q38798654
Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trialsAcid-base and electrolyte disorders associated with the use of antidiabetic drugs.Implications of the EMPA-REG Trial for Clinical Care and Research.Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.SGLT2 Inhibitors: Benefit/Risk Balance.Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.Bone Fractures with Sodium-Glucose Co-transporter-2 Inhibitors: How Real is the Risk?Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes.Effect of diuretics on renal tubular transport of calcium and magnesium.Review article: effects of type 2 diabetes therapies on bone metabolism.Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus.Complex interplay among adiposity, insulin resistance and bone health.The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes.SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists.
P2860

The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus.

Item
http://www.wikidata.org/entity/Q38798654
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The effects of canagliflozin, ...... with type 2 diabetes mellitus.
@en
type
label
The effects of canagliflozin, ...... with type 2 diabetes mellitus.
@en
prefLabel
The effects of canagliflozin, ...... with type 2 diabetes mellitus.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P921
P356
P1433
P1476
The effects of canagliflozin, ...... with type 2 diabetes mellitus.
@en
P2093
P2860
P304
P31
P356
10.1080/03007995.2016.1174841
P407
P433
P478
P577
P698
P921